Polygenic Prediction of Peripheral Artery Disease and Major Adverse Limb Events.

IF 14.1 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
Alyssa M Flores,Yunfeng Ruan,Anika Misra,So Mi Jemma Cho,Margaret S Selvaraj,Tiffany R Bellomo,Tetsushi Nakao,Kenneth Rosenfield,Matthew Eagleton,Whitney Hornsby,Aniruddh P Patel,Pradeep Natarajan
{"title":"Polygenic Prediction of Peripheral Artery Disease and Major Adverse Limb Events.","authors":"Alyssa M Flores,Yunfeng Ruan,Anika Misra,So Mi Jemma Cho,Margaret S Selvaraj,Tiffany R Bellomo,Tetsushi Nakao,Kenneth Rosenfield,Matthew Eagleton,Whitney Hornsby,Aniruddh P Patel,Pradeep Natarajan","doi":"10.1001/jamacardio.2025.1182","DOIUrl":null,"url":null,"abstract":"Importance\r\nPeripheral artery disease (PAD) is a heritable atherosclerotic condition associated with functional decline and high risk for limb loss. With growing knowledge of the genetic basis for PAD and related risk factors, there is potential opportunity to identify individuals at high risk using polygenic risk scores (PRSs).\r\n\r\nObjective\r\nTo develop a novel integrated, multiancestry polygenic score for PAD (PRS-PAD) and evaluate its risk estimation for PAD and major adverse limb events in 3 populations.\r\n\r\nDesign, Setting, and Participants\r\nThis longitudinal cohort study was conducted among individuals with genotyping and electronic health record data in the UK Biobank (2006-2021), All of Us (AoU, 2018-2022), and the Mass General Brigham Biobank (MGBB, 2010-2023). Data were analyzed from July 2023 to February 2025.\r\n\r\nExposures\r\nPRS-PAD, previously published PAD polygenic scores, and clinical risk factors.\r\n\r\nMain Outcomes and Measures\r\nThe primary outcomes were PAD and major adverse limb events, defined as a surrogate of major amputation and acute limb ischemia.\r\n\r\nResults\r\nThe study populations included 400 533 individuals from the UK Biobank (median [IQR] age, 58.2 [45.0-71.4] years; 216 215 female participants [53.9%]), 218 500 from AoU (median [IQR] age, 53.6 [37.7-65.0] years; 132 647 female participants [60.7%]), and 32 982 from MGBB (median [IQR] age, 56.0 [32.0-80.0] years; 18 277 female participants [55.4%]). In the UK Biobank validation cohort, PRS-PAD was associated with an odds ratio [OR] per SD increase of 1.63 (95% CI, 1.60-1.68; P < .001). After adjusting for clinical risk factors, the OR for the top 20% of PRS-PAD was 1.68 (95% CI, 1.62-1.74; P < .001) compared to the remainder of the population. Among PAD cases without a history of diabetes, smoking, or chronic kidney disease (n = 3645), 1097 individuals (30.1%) had a high PRS-PAD (top 20%). In incident disease analysis, PRS-PAD improved discrimination (C statistic, 0.761), which was nearly equivalent to the performances of diabetes (C statistic, 0.760) and smoking (C statistic, 0.765). Among individuals with prevalent PAD, high PRS-PAD was associated with an increased risk of incident major adverse limb events in the UK Biobank (hazard ratio [HR], 1.75; 95% CI, 1.18-2.57; P = .005), MGBB (HR, 1.56; 95% CI, 1.06-2.30; P = .02), and AoU (HR, 1.57; 95% CI, 1.06-2.33; P = .03).\r\n\r\nConclusions and Relevance\r\nThis cohort study develops a new PRS that stratifies risk of PAD and adverse limb outcomes. Incorporating polygenic risk into PAD care warrants further investigation to guide screening and tailor management to prevent major adverse limb events.","PeriodicalId":14657,"journal":{"name":"JAMA cardiology","volume":"135 1","pages":""},"PeriodicalIF":14.1000,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMA cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1001/jamacardio.2025.1182","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Importance Peripheral artery disease (PAD) is a heritable atherosclerotic condition associated with functional decline and high risk for limb loss. With growing knowledge of the genetic basis for PAD and related risk factors, there is potential opportunity to identify individuals at high risk using polygenic risk scores (PRSs). Objective To develop a novel integrated, multiancestry polygenic score for PAD (PRS-PAD) and evaluate its risk estimation for PAD and major adverse limb events in 3 populations. Design, Setting, and Participants This longitudinal cohort study was conducted among individuals with genotyping and electronic health record data in the UK Biobank (2006-2021), All of Us (AoU, 2018-2022), and the Mass General Brigham Biobank (MGBB, 2010-2023). Data were analyzed from July 2023 to February 2025. Exposures PRS-PAD, previously published PAD polygenic scores, and clinical risk factors. Main Outcomes and Measures The primary outcomes were PAD and major adverse limb events, defined as a surrogate of major amputation and acute limb ischemia. Results The study populations included 400 533 individuals from the UK Biobank (median [IQR] age, 58.2 [45.0-71.4] years; 216 215 female participants [53.9%]), 218 500 from AoU (median [IQR] age, 53.6 [37.7-65.0] years; 132 647 female participants [60.7%]), and 32 982 from MGBB (median [IQR] age, 56.0 [32.0-80.0] years; 18 277 female participants [55.4%]). In the UK Biobank validation cohort, PRS-PAD was associated with an odds ratio [OR] per SD increase of 1.63 (95% CI, 1.60-1.68; P < .001). After adjusting for clinical risk factors, the OR for the top 20% of PRS-PAD was 1.68 (95% CI, 1.62-1.74; P < .001) compared to the remainder of the population. Among PAD cases without a history of diabetes, smoking, or chronic kidney disease (n = 3645), 1097 individuals (30.1%) had a high PRS-PAD (top 20%). In incident disease analysis, PRS-PAD improved discrimination (C statistic, 0.761), which was nearly equivalent to the performances of diabetes (C statistic, 0.760) and smoking (C statistic, 0.765). Among individuals with prevalent PAD, high PRS-PAD was associated with an increased risk of incident major adverse limb events in the UK Biobank (hazard ratio [HR], 1.75; 95% CI, 1.18-2.57; P = .005), MGBB (HR, 1.56; 95% CI, 1.06-2.30; P = .02), and AoU (HR, 1.57; 95% CI, 1.06-2.33; P = .03). Conclusions and Relevance This cohort study develops a new PRS that stratifies risk of PAD and adverse limb outcomes. Incorporating polygenic risk into PAD care warrants further investigation to guide screening and tailor management to prevent major adverse limb events.
外周动脉疾病和主要肢体不良事件的多基因预测。
外周动脉疾病(PAD)是一种遗传性动脉粥样硬化疾病,与功能下降和肢体丧失的高风险相关。随着人们对PAD的遗传基础和相关危险因素的了解不断增加,使用多基因风险评分(PRSs)来识别高风险个体的可能性越来越大。目的建立一种新的综合多祖先多基因PAD评分方法(PRS-PAD),并评估其对3个人群PAD和主要肢体不良事件的风险评估。设计、环境和参与者本纵向队列研究在英国生物银行(2006-2021)、我们所有人(AoU, 2018-2022)和麻省总医院布里格姆生物银行(MGBB, 2010-2023)的基因分型和电子健康记录数据的个体中进行。数据分析时间为2023年7月至2025年2月。exsuresprs -PAD,先前发表的PAD多基因评分和临床危险因素。主要结局和测量主要结局是PAD和严重肢体不良事件,定义为严重截肢和急性肢体缺血的替代指标。结果研究人群包括400 533名来自UK Biobank的个体(中位[IQR]年龄为58.2[45.0-71.4]岁;216名 女性215名[53.9%]),218名 500名来自AoU(中位[IQR]年龄为53.6[37.7-65.0]岁;132名 647名女性参与者[60.7%]),32名 982名来自MGBB(中位[IQR]年龄:56.0[32.0-80.0]岁;18 女性277例[55.4%])。在英国生物库验证队列中,PRS-PAD与每SD增加1.63的优势比[OR]相关(95% CI, 1.60-1.68;p < 0.001)。调整临床危险因素后,前20%的PRS-PAD患者的OR为1.68 (95% CI, 1.62-1.74;P < 0.001)。在没有糖尿病、吸烟或慢性肾脏疾病史的PAD患者中(n = 3645), 1097人(30.1%)有高PRS-PAD(前20%)。在事件疾病分析中,PRS-PAD提高了辨别性(C统计量,0.761),几乎等同于糖尿病(C统计量,0.760)和吸烟(C统计量,0.765)的表现。在普遍存在PAD的个体中,高PRS-PAD与UK Biobank中发生主要肢体不良事件的风险增加相关(风险比[HR], 1.75;95% ci, 1.18-2.57;P = .005), MGBB (hr, 1.56;95% ci, 1.06-2.30;P = .02), AoU (HR, 1.57;95% ci, 1.06-2.33;p = .03)。结论和相关性本队列研究开发了一种新的PRS,可对PAD的风险和不良肢体预后进行分层。将多基因风险纳入PAD护理需要进一步研究,以指导筛查和定制管理,以预防主要的肢体不良事件。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
JAMA cardiology
JAMA cardiology Medicine-Cardiology and Cardiovascular Medicine
CiteScore
45.80
自引率
1.70%
发文量
264
期刊介绍: JAMA Cardiology, an international peer-reviewed journal, serves as the premier publication for clinical investigators, clinicians, and trainees in cardiovascular medicine worldwide. As a member of the JAMA Network, it aligns with a consortium of peer-reviewed general medical and specialty publications. Published online weekly, every Wednesday, and in 12 print/online issues annually, JAMA Cardiology attracts over 4.3 million annual article views and downloads. Research articles become freely accessible online 12 months post-publication without any author fees. Moreover, the online version is readily accessible to institutions in developing countries through the World Health Organization's HINARI program. Positioned at the intersection of clinical investigation, actionable clinical science, and clinical practice, JAMA Cardiology prioritizes traditional and evolving cardiovascular medicine, alongside evidence-based health policy. It places particular emphasis on health equity, especially when grounded in original science, as a top editorial priority.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信